Nocif Joseph Espat, MD

Assistant Dean

Nocif Espat
401.456.2000
jespat@bu.edu
View full profile at BUMC

Biography

Dr. Espat graduated from the University of Florida College of Medicine in 1990. Dr. Espat works in Providence, RI and specializes in Hematology/Oncology. Dr. Espat is affiliated with Roger Williams Medical Center.

Other Positions

  • Professor, Surgery, Boston University Chobanian & Avedisian School of Medicine

Websites

Education

  • University of Florida College of Medicine, MD
  • University of Illinois, MS
  • University of South Florida, BA

Publications

  • Published on 2/7/2022

    Winkler CS, Hardaway JC, Ceyhan ME, Espat NJ, Saied Calvino A. Decreasing colorectal cancer screening disparities: A culturally tailored patient navigation program for Hispanic patients. Cancer. 2022 May 01; 128(9):1820-1825. PMID: 35128638.

    Read at: PubMed
  • Published on 4/1/2020

    Jeyarajah DR, Doyle MBM, Espat NJ, Hansen PD, Iannitti DA, Kim J, Thambi-Pillai T, Visser BC. Role of yttrium-90 selective internal radiation therapy in the treatment of liver-dominant metastatic colorectal cancer: an evidence-based expert consensus algorithm. J Gastrointest Oncol. 2020 Apr; 11(2):443-460. PMID: 32399284.

    Read at: PubMed
  • Published on 2/13/2020

    Patel A, Espat NJ, Somasundar P. Fibrolamellar Carcinoma: Novel Insights into a Rare Subtype. Ann Surg Oncol. 2020 Jun; 27(6):1733-1734. PMID: 32056041.

    Read at: PubMed
  • Published on 6/3/2019

    Katz SC, Hardaway J, Prince E, Guha P, Cunetta M, Moody A, Wang LJ, Armenio V, Espat NJ, Junghans RP. HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA+ liver metastases. Cancer Gene Ther. 2020 05; 27(5):341-355. PMID: 31155611.

    Read at: PubMed
  • Published on 12/1/2018

    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial. JAMA Oncol. 2018 12 01; 4(12):e184060. PMID: 30383140.

    Read at: PubMed
  • Published on 8/29/2018

    Guha P, Gardell J, Darpolor J, Cunetta M, Lima M, Miller G, Espat NJ, Junghans RP, Katz SC. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells. Oncogene. 2019 01; 38(4):533-548. PMID: 30158673.

    Read at: PubMed
  • Published on 6/1/2017

    Ahmad A, Reha J, Saied A, Espat NJ, Somasundar P, Katz SC. Association of primary tumor lymph node ratio with burden of liver metastases and survival in stage IV colorectal cancer. Hepatobiliary Surg Nutr. 2017 Jun; 6(3):154-161. PMID: 28652998.

    Read at: PubMed
  • Published on 5/25/2017

    Guha P, Cunetta M, Somasundar P, Espat NJ, Junghans RP, Katz SC. Frontline Science: Functionally impaired geriatric CAR-T cells rescued by increased a5ß1 integrin expression. J Leukoc Biol. 2017 08; 102(2):201-208. PMID: 28546503.

    Read at: PubMed
  • Published on 6/21/2016

    Ahmad A, Reha J, Somasundar P, Espat NJ, Katz SC. Predictors of surgical non-referral for colorectal liver metastases. J Surg Res. 2016 09; 205(1):198-203. PMID: 27621019.

    Read at: PubMed
  • Published on 5/20/2016

    Thorn M, Guha P, Cunetta M, Espat NJ, Miller G, Junghans RP, Katz SC. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases. Cancer Gene Ther. 2016 06; 23(6):188-98. PMID: 27199222.

    Read at: PubMed

View 105 more publications: View full profile at BUMC

View all profiles